| Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial HE Gendelman, Y Zhang, P Santamaria, KE Olson, CR Schutt, D Bhatti, ... NPJ Parkinson's disease 3 (1), 10, 2017 | 144 | 2017 |
| CD4+ effector T cells accelerate Alzheimer’s disease in mice J Machhi, P Yeapuri, Y Lu, E Foster, R Chikhale, J Herskovitz, ... Journal of neuroinflammation 18, 1-23, 2021 | 92 | 2021 |
| Cathepsin B improves ß-amyloidosis and learning and memory in models of Alzheimer’s disease CM Embury, B Dyavarshetty, Y Lu, JL Wiederin, P Ciborowski, ... Journal of Neuroimmune Pharmacology 12, 340-352, 2017 | 79 | 2017 |
| Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer’s disease mice T Kiyota, J Machhi, Y Lu, B Dyavarshetty, M Nemati, I Yokoyama, ... Journal of neuroimmunology 319, 80-92, 2018 | 70 | 2018 |
| Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability H Wen, Y Lu, H Yao, S Buch PloS one 6 (6), e21707, 2011 | 59 | 2011 |
| Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120 Y Yang, H Yao, Y Lu, C Wang, S Buch PloS one 5 (10), e13427, 2010 | 55 | 2010 |
| AAV2/1 CD74 gene transfer reduces β-amyloidosis and improves learning and memory in a mouse model of Alzheimer's disease T Kiyota, G Zhang, CM Morrison, ME Bosch, RA Weir, Y Lu, W Dong, ... Molecular Therapy 23 (11), 1712-1721, 2015 | 51 | 2015 |
| Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease KE Olson, KL Namminga, Y Lu, AD Schwab, MJ Thurston, ... EBioMedicine 67, 2021 | 46 | 2021 |
| A synthetic agonist to vasoactive intestinal peptide receptor-2 induces regulatory T cell neuroprotective activities in models of Parkinson’s disease RL Mosley, Y Lu, KE Olson, J Machhi, W Yan, KL Namminga, JR Smith, ... Frontiers in Cellular Neuroscience 13, 421, 2019 | 44 | 2019 |
| URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer’s disease T Kiyota, J Machhi, Y Lu, B Dyavarshetty, M Nemati, G Zhang, RL Mosley, ... Journal of Neuroinflammation 15, 1-14, 2018 | 44 | 2018 |
| Granulocyte-macrophage colony-stimulating factor mRNA and neuroprotective immunity in Parkinson's disease KE Olson, KL Namminga, Y Lu, MJ Thurston, AD Schwab, S de Picciotto, ... Biomaterials 272, 120786, 2021 | 43 | 2021 |
| The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation W Dong, CM Embury, Y Lu, SM Whitmire, B Dyavarshetty, HA Gelbard, ... Journal of Neuroinflammation 13, 1-11, 2016 | 35 | 2016 |
| Neuroprotective activities of long-acting granulocyte–macrophage colony-stimulating factor (mPDM608) in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-intoxicated mice KE Olson, KL Namminga, AD Schwab, MJ Thurston, Y Lu, A Woods, L Lei, ... Neurotherapeutics 17 (4), 1861-1877, 2020 | 29 | 2020 |
| Nanogel-conjugated reverse transcriptase inhibitors and their combinations as novel antiviral agents with increased efficacy against HIV-1 infection TH Senanayake, S Gorantla, E Makarov, Y Lu, G Warren, SV Vinogradov Molecular pharmaceutics 12 (12), 4226-4236, 2015 | 28 | 2015 |
| Amphiphilic cationic nanogels as brain-targeted carriers for activated nucleoside reverse transcriptase inhibitors G Warren, E Makarov, Y Lu, T Senanayake, K Rivera, S Gorantla, ... Journal of Neuroimmune Pharmacology 10, 88-101, 2015 | 28 | 2015 |
| Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice P Yeapuri, J Machhi, Y Lu, MM Abdelmoaty, R Kadry, M Patel, S Bhattarai, ... Molecular neurodegeneration 18 (1), 97, 2023 | 22 | 2023 |
| Europium-doped cerium oxide nanoparticles for microglial amyloid beta clearance and homeostasis J Machhi, P Yeapuri, M Markovic, M Patel, W Yan, Y Lu, JD Cohen, ... ACS chemical neuroscience 13 (8), 1232-1244, 2022 | 22 | 2022 |
| Development of an extended half-life GM-CSF fusion protein for Parkinson's disease P Yeapuri, KE Olson, Y Lu, MM Abdelmoaty, KL Namminga, M Markovic, ... Journal of Controlled Release 348, 951-965, 2022 | 17 | 2022 |
| An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers KE Olson, MM Abdelmoaty, KL Namminga, Y Lu, H Obaro, P Santamaria, ... Translational Neurodegeneration 12 (1), 26, 2023 | 14 | 2023 |
| Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy TH Senanayake, Y Lu, A Bohling, S Raja, H Band, SV Vinogradov Pharmaceutical research 31, 1605-1615, 2014 | 10 | 2014 |
